Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Ipilimumab is a recombinant, human monoclonal antibody that inhibits cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and thus, potentiates anti-tumor T-cell response. This study objective was to assess overall efficacy and safety profile of Ipilimumab in metastatic melanoma patients in community settings.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
